The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.
The chart below shows how we grade BioHarvest Sciences (BHST) across the board compared to its closest peers.
Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.
See how BioHarvest Sciences compares to its peers in these key performance metrics from Benzinga Rankings.
The two main factors that we consider when analyzing past performance is overall return and volatility
Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.
This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.
BioHarvest Sciences (BHST) sharpe ratio over the past 5 years is -0.4109 which is considered to be above average compared to the peer average of -0.4163

